Vanguard Group’s GenMark Diagnostics, Inc GNMK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-3,670,817
| Closed | -$87.7M | – | 4487 |
|
|
2021
Q1 | $87.7M | Sell |
3,670,817
-827,087
| -18% | -$15.4M | ﹤0.01% | 2019 |
|
|
2020
Q4 | $65.7M | Buy |
4,497,904
+129,771
| +3% | +$1.72M | ﹤0.01% | 2060 |
|
|
2020
Q3 | $62M | Buy |
4,368,133
+645,589
| +17% | +$9.87M | ﹤0.01% | 1904 |
|
|
2020
Q2 | $54.8M | Buy |
3,722,544
+843,993
| +29% | +$8.57M | ﹤0.01% | 1967 |
|
|
2020
Q1 | $11.9M | Sell |
2,878,551
-285,244
| -9% | -$1.34M | ﹤0.01% | 2535 |
|
|
2019
Q4 | $15.2M | Buy |
3,163,795
+369,323
| +13% | +$2.04M | ﹤0.01% | 2658 |
|
|
2019
Q3 | $16.9M | Buy |
2,794,472
+88,110
| +3% | +$550K | ﹤0.01% | 2561 |
|
|
2019
Q2 | $17.6M | Sell |
2,706,362
-18,693
| -0.7% | -$132K | ﹤0.01% | 2581 |
|
|
2019
Q1 | $19.3M | Sell |
2,725,055
-25,109
| -0.9% | -$165K | ﹤0.01% | 2526 |
|
|
2018
Q4 | $13.4M | Buy |
2,750,164
+136,951
| +5% | +$713K | ﹤0.01% | 2627 |
|
|
2018
Q3 | $19.2M | Buy |
2,613,213
+34,940
| +1% | +$256K | ﹤0.01% | 2596 |
|
|
2018
Q2 | $16.5M | Buy |
2,578,273
+48,457
| +2% | +$320K | ﹤0.01% | 2652 |
|
|
2018
Q1 | $13.8M | Buy |
2,529,816
+90,153
| +4% | +$448K | ﹤0.01% | 2657 |
|
|
2017
Q4 | $10.2M | Buy |
2,439,663
+77,562
| +3% | +$467K | ﹤0.01% | 2808 |
|
|
2017
Q3 | $22.7M | Buy |
2,362,101
+192,625
| +9% | +$2M | ﹤0.01% | 2437 |
|
|
2017
Q2 | $25.7M | Buy |
2,169,476
+212,795
| +11% | +$2.72M | ﹤0.01% | 2351 |
|
|
2017
Q1 | $25.1M | Buy |
1,956,681
+58,691
| +3% | +$706K | ﹤0.01% | 2347 |
|
|
2016
Q4 | $23.2M | Buy |
1,897,990
+240,120
| +14% | +$2.85M | ﹤0.01% | 2362 |
|
|
2016
Q3 | $19.6M | Buy |
1,657,870
+16,558
| +1% | +$160K | ﹤0.01% | 2370 |
|
|
2016
Q2 | $14.3M | Buy |
1,641,312
+104,864
| +7% | +$719K | ﹤0.01% | 2479 |
|
|
2016
Q1 | $8.1M | Buy |
1,536,448
+50,011
| +3% | +$278K | ﹤0.01% | 2726 |
|
|
2015
Q4 | $11.5M | Buy |
1,486,437
+61,708
| +4% | +$474K | ﹤0.01% | 2562 |
|
|
2015
Q3 | $11.2M | Buy |
1,424,729
+122,413
| +9% | +$1.13M | ﹤0.01% | 2553 |
|
|
2015
Q2 | $11.8M | Buy |
1,302,316
+32,918
| +3% | +$332K | ﹤0.01% | 2589 |
|
|
2015
Q1 | $16.5M | Buy |
1,269,398
+81,340
| +7% | +$1.06M | ﹤0.01% | 2405 |
|
|
2014
Q4 | $16.2M | Buy |
1,188,058
+47,851
| +4% | +$535K | ﹤0.01% | 2331 |
|
|
2014
Q3 | $10.2M | Buy |
1,140,207
+46,576
| +4% | +$501K | ﹤0.01% | 2483 |
|
|
2014
Q2 | $14.8M | Buy |
1,093,631
+45,163
| +4% | +$471K | ﹤0.01% | 2337 |
|
|
2014
Q1 | $10.4M | Buy |
1,048,468
+145,610
| +16% | +$1.81M | ﹤0.01% | 2470 |
|
|
2013
Q4 | $12M | Buy |
902,858
+22,510
| +3% | +$273K | ﹤0.01% | 2381 |
|
|
2013
Q3 | $10.7M | Buy |
880,348
+157,192
| +22% | +$1.69M | ﹤0.01% | 2368 |
|
|
2013
Q2 | $7.48M | Buy |
+723,156
| New | +$9.97M | ﹤0.01% | 2465 |
|
Vanguard Group's GNMK Position: Q2 2021 in Review
Vanguard Group sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2021, closing a stake of 3,670,817 shares — an estimated $87.7M sold.
Vanguard Group first reported a position in GNMK in Q2 2013 and held it in 32 quarters. The position peaked at $87.7M in Q1 2021. 0 funds tracked by Wall St. Rank hold GNMK as of Q2 2021.
- Vanguard Group reported no remaining GenMark Diagnostics, Inc position as of Q2 2021 after selling out during the quarter.
- Vanguard Group sold 3,670,817 GenMark Diagnostics, Inc shares in Q2 2021, an estimated $87.7M.
- Vanguard Group first reported a position in GenMark Diagnostics, Inc in Q2 2013 and held it in 32 quarters.
- Vanguard Group's GenMark Diagnostics, Inc position peaked at $87.7M in Q1 2021.
- 0 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2021.
Based on Vanguard Group's 13F filing for Q2 2021, filed 13 Aug 2021.